0000000000967886
AUTHOR
J.a. García-velasco
High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist.
High daily doses of gonadotrophin-releasing hormone (GnRH) antagonists during the follicular phase of ovarian stimulation were associated with low implantation rates. To test if this occurred because of profound pituitary suppression, the pituitary response was suppressed with a high-dose GnRH antagonist and recombinant LH (rLH) was added back to correct the implantation rate. An open-label, randomized, controlled, prospective clinical study in 60 patients undergoing IVF was performed. GnRH antagonist was initiated on day 6 of stimulation (2 mg/day) together with 375 IU rLH, and maintained until the day of HCG administration. Controls received 0.25 mg/day GnRH antagonist. Fluctuating LH con…
El coasting es eficaz en la prevención del síndrome de hiperestimulación ovárica y no afecta a los resultados de la fecundación in vitro
Resumen Objetivo Describir los resultados de los ciclos de FIV/ICSI en pacientes sometidas a coasting por hiperrespuesta a la estimulacion ovarica controlada (EOC), asi como la frecuencia de presentacion y severidad del sindrome de hiperestimulacion ovarica (SHO). Ademas, evaluar si la duracion del coasting compromete los resultados del ciclo Pacientes y metodos Estudio retrospectivo de 42 ciclos de fecundacion in vitro de pacientes con hiperrespuesta a la EOC sometidas a coasting (mantener la administracion del analogo de la GnRH mientras se suprime la administracion de gonadotropinas) hasta que los valores sericos de estradiol (E2) disminuyan a un valor “seguro” para administrar la hCG y …
Identification and Quantification of Dopamine Receptor 2 in Human Eutopic and Ectopic Endometrium: A Novel Molecular Target for Endometriosis Therapy1
Previous studies in an experimental mouse model of endometriosis have shown that the dopamine agonist (DA) cabergoline (Cb2) reduces angiogenesis and endometriotic lesions, hypothetically binding to the dopamine receptor type-2 (DRD2). To date, this has not been described in human endometrium and/or endometriotic lesions. Thus, we aimed to investigate the presence of DRD2 in said tissues. Endometrium fragments were implanted in nude mice treated with different doses of Cb2. Polymerase chain reaction assays and immunohistochemistry were performed to analyze the gene and protein expressions (respectively) of DRD2, VEGF, and VEGF receptor-2 (KDR). In addition, lesions and endometrium from wome…